Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MediciNova
(NASDAQ:MNOV)
Intraday
$1.33
0.01
[0.76%]
After-Hours
$1.33
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.33
0.01
[0.76%]
At close: Apr 23
$1.33
0
[0.00%]
After Hours: 7:40PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for MediciNova Stock (NASDAQ:MNOV)
MediciNova Stock (NASDAQ: MNOV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 05, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Apr 5, 2024, 4:31PM
Wednesday, April 03, 2024
Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
Benzinga Newsdesk
-
Apr 3, 2024, 2:45AM
Wednesday, March 27, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Mar 27, 2024, 9:05AM
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 27, 2024, 8:14AM
Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
Benzinga Newsdesk
-
Mar 27, 2024, 2:40AM
Thursday, March 21, 2024
Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
Benzinga Newsdesk
-
Mar 21, 2024, 3:14AM
Tuesday, March 12, 2024
MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology
Benzinga Newsdesk
-
Mar 12, 2024, 6:36AM
Tuesday, February 27, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Feb 27, 2024, 8:06AM
Friday, February 16, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Feb 16, 2024, 8:06AM
Tuesday, February 13, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Feb 13, 2024, 8:06AM
Wednesday, January 17, 2024
MediciNova Secures Notice Of Grant For New Patent Covering MN-166 (ibudilast) For Treatment Of Macular Injury In China
Benzinga Newsdesk
-
Jan 17, 2024, 6:03AM
Thursday, December 21, 2023
MediciNova Says Abstract Regarding MN-166 (ibudilast) In Chlorine Gas-induced Lung Injury Accepted For Presentation At The 63rd Annual Meeting Of The Society Of Toxicology
Benzinga Newsdesk
-
Dec 21, 2023, 6:04PM
Wednesday, December 06, 2023
MediciNova Receives Notice Of Decision To Grant For New Patent Covering MN-166 (ibudilast) For Treatment Of Progressive MS In Europe
Benzinga Newsdesk
-
Dec 6, 2023, 6:02PM
Monday, November 20, 2023
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Nov 20, 2023, 2:35PM
Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?
Vandana Singh
-
Nov 20, 2023, 12:01PM
MediciNova shares are trading higher after the company announced new data and results from its Phase 2 MN-166 trial in glioblastoma.
Benzinga Newsdesk
-
Nov 20, 2023, 10:08AM
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Nov 20, 2023, 8:19AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Nov 20, 2023, 8:06AM
Sunday, November 19, 2023
MediciNova Announces New Data And Results Of A Phase 2 Clinical Trial Of MN-166 In Glioblastoma Presented At The 28th Annual Meeting Of The Society For Neuro-Oncology
Benzinga Newsdesk
-
Nov 19, 2023, 10:03PM
Friday, October 27, 2023
MediciNova's Collaborator Genzyme Initiates Clinical Development Of A Gene Therapy Product For The Treatment Of Phenylketonuria
Benzinga Newsdesk
-
Oct 27, 2023, 1:50AM
Wednesday, October 11, 2023
MediciNova Receives Notice Of Allowance From The Canadian Intellectual Property Office For A New Patent Application Covering The Combination Of MN-166 And Riluzole For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Benzinga Newsdesk
-
Oct 11, 2023, 2:26AM
Thursday, October 05, 2023
MediciNova Hits Milestone, Secures $1M Payment From Genzyme Amid Gene Therapy Progress
Benzinga Newsdesk
-
Oct 5, 2023, 2:08AM
Thursday, September 28, 2023
MediciNova Announces Results Of Studies Under BARDA Contract To Develop MN 166 As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury
Benzinga Newsdesk
-
Sep 28, 2023, 2:12AM
Monday, August 21, 2023
Watching MediciNova; Zacks Small-Cap Research Sets $26 Price Valuation; Says This Model Is Highly Dependent Upon Continued Clinical Success Of The Co's Assets And Will Be Adjusted Accordingly Based Upon Future Clinical Results
Happy Mohamed
-
Aug 21, 2023, 10:11AM
Thursday, August 17, 2023
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Benzinga Newsdesk
-
Aug 17, 2023, 4:00AM
Wednesday, August 09, 2023
Director at MediciNova Acquires Company Stock Options Worth 18,333 Shares
Benzinga Insights
-
Aug 9, 2023, 11:02AM
Thursday, June 29, 2023
Medicinova Announced That Principal Investigator Presented The Results Of The Phase 2B Trial Of Mn-166 (Ibudilast) In Alcohol Use Disorder At The 46th Annual Research Society On Alcoholism Scientific Meeting
Benzinga Newsdesk
-
Jun 29, 2023, 6:07AM
Friday, June 16, 2023
Board Member at MediciNova Acquires Company Stock Options Worth 20,000 Shares
Benzinga Insights
-
Jun 16, 2023, 11:04AM
Director at MediciNova Acquires Company Stock Options Worth 20,000 Shares
Benzinga Insights
-
Jun 16, 2023, 11:04AM
Sunday, May 14, 2023
MediciNova Received Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
Charles Gross
-
May 14, 2023, 7:09PM
Sunday, April 30, 2023
MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 For The Treatment Of Advanced NASH In Canada
Benzinga Newsdesk
-
Apr 30, 2023, 7:58PM
Friday, March 10, 2023
Reported Late Thursday March 9, MediciNova Announces Additional Extension Of BARDA Contract To Develop MN-166 As A Medical Countermeasure Against Chlorine Gas-induced Lung Injury; Contract Was Amended To Extend The Period Of Performance Until May 31, 2023
Happy Mohamed
-
Mar 10, 2023, 12:27AM
Wednesday, February 22, 2023
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Feb 22, 2023, 8:06AM
Tuesday, February 21, 2023
Medicinova Presented New Data Regarding Tumor Tissue Analysis And Clinical Outcome From A Glioblastoma Clinical Trial, MN-166-GBM-1201 Phase 1/2 Study
Benzinga Newsdesk
-
Feb 21, 2023, 3:42AM
Wednesday, February 08, 2023
MediciNova Announces Health Canada Grants Authorization To Commence Multi-Arm Phase 2/3 Clinical Trial To Evaluate MN-166 In Long COVID
Michael Horton
-
Feb 8, 2023, 6:00PM
Monday, January 30, 2023
MediciNova Announces Completion Of Enrollment In The Phase 2b Clinical Trial Of MN 166 In Alcohol Use Disorder
Michael Horton
-
Jan 30, 2023, 6:03PM
Wednesday, January 25, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jan 25, 2023, 4:31PM
Wednesday, January 11, 2023
Reported Late Tuesday, MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For The Treatment Of Scleroderma And Systemic Sclerosis In Canada
Benzinga Newsdesk
-
Jan 11, 2023, 12:47AM
Tuesday, January 10, 2023
Reported Late Monday, MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia In Brazil
Benzinga Newsdesk
-
Jan 10, 2023, 12:35AM
Friday, January 06, 2023
Reported Late Thursday, MediciNova To Meet With U.S. FDA To Discuss Clinical Development Of A Parenteral Formulation Of MN-166
Benzinga Newsdesk
-
Jan 6, 2023, 12:36AM
Wednesday, December 28, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Dec 28, 2022, 11:23AM
Wednesday, December 07, 2022
Reported Late Tuesday, MediciNova Announces Additional Results Regarding The Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress, The Annual Meeting Of The International Diabetes Federation
Benzinga Newsdesk
-
Dec 7, 2022, 1:11AM
Monday, December 05, 2022
MediciNova Announces Results From Secondary Analysis Of Phase 2 Trial Of MN-166 (ibudilast) Published In The American Journal Of Drug And Alcohol Abuse
Michael Horton
-
Dec 5, 2022, 6:01PM
Friday, November 18, 2022
Watching MediciNova; Zacks Small-Cap Research Sets $27.00 Price Valuation
Benzinga Newsdesk
-
Nov 18, 2022, 10:07AM
Wednesday, October 12, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 12, 2022, 1:32PM
Tuesday, October 11, 2022
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 11, 2022, 12:47PM
Wednesday, September 14, 2022
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
Vandana Singh
-
Sep 14, 2022, 9:03AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Sep 14, 2022, 8:08AM
Tuesday, September 13, 2022
MediciNova Received a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
Charles Gross
-
Sep 13, 2022, 7:59PM
Wednesday, September 07, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 7, 2022, 1:08PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch